Last reviewed · How we verify
Tinzaparin Injectable Solution
Tinzaparin is a low molecular weight heparin that works by inhibiting coagulation factors to prevent blood clot formation.
Tinzaparin is a low molecular weight heparin that works by inhibiting coagulation factors to prevent blood clot formation. Used for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Prophylaxis and treatment of thrombosis in patients undergoing hip or knee replacement surgery.
At a glance
| Generic name | Tinzaparin Injectable Solution |
|---|---|
| Also known as | Innohep® |
| Sponsor | Queen Mary University of London |
| Drug class | Low molecular weight heparin |
| Target | Coagulation factors (IIa and Xa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It achieves this by binding to antithrombin III, which in turn inhibits the activity of coagulation factors such as factor IIa and factor Xa. This results in a decrease in the formation of blood clots and a reduction in the risk of thrombotic events.
Approved indications
- Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism
- Prophylaxis and treatment of thrombosis in patients undergoing hip or knee replacement surgery
Common side effects
- Hemorrhage
- Thrombocytopenia
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients (NA)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum (NA)
- Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome (NA)
- Enhanced Recovery After Surgery(ERAS) Following Gynaecological Oncology Surgery in a Tertiary Level Hospital (NA)
- A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke (PHASE2)
- Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer (PHASE2)
- Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tinzaparin Injectable Solution CI brief — competitive landscape report
- Tinzaparin Injectable Solution updates RSS · CI watch RSS
- Queen Mary University of London portfolio CI